Sacubitril/Valsartan for Cardioprotection in Breast Cancer (MAINSTREAM): Design and Rationale of the Randomized Trial
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14466 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Mateusz Tajstra und 17 weiteren Autor:innen. Beteiligte Einrichtung: 3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Aminobutyrates, Biphenyl Compounds, Valsartan, Drug Combinations. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agencja Badań Medycznych.
Abstract (Originalsprache)
Aims
In recent years, survival in patients with breast cancer has increased. Despite the improvement in outcomes of those patients, the risk of treatment-related cardiotoxicity remains high, and its presence has been associated with a higher risk of treatment termination and thus lower therapeutic efficacy. Prior trials demonstrated that a preventive initiation of heart failure drugs, including the renin–angiotensin–aldosterone inhibitors, might reduce the risk of treatment-related cardiotoxicity. However, to date, no study investigated the efficacy of sacubitril/valsartan, a novel antineurohormonal drug shown to be superior to the previous therapies, in the prevention of cardiotoxicity in patients with early-stage breast cancer, which is the aim of the trial. Methods and results MAINSTREAM is a randomized, placebo-controlled, double-blind, multicentre, clinical trial. After the run-in period, a total of 480 patients with early breast cancer undergoing treatment with anthracyclines and/or anti-human epidermal growth factor receptor 2 drugs will be randomized to the highest tolerated dose of sacubitril/valsartan, being preferably 97/103 mg twice daily or placebo in 1:1 ratio. The patients will be monitored, including routine transthoracic echocardiography (TTE) and laboratory biomarker monitoring, for 24 months. The primary endpoint of the trial will be the occurrence of a decrease in left ventricular ejection fraction by ≥5% in TTE within 24 months. The key secondary endpoints will be the composite endpoint of death from any cause or hospitalization for heart failure, as well as other imaging, laboratory, and clinical outcomes, including the occurrence of the cancer therapy-related cardiac dysfunction resulting in the necessity to initiate treatment. The first patients are expected to be recruited in the coming months, and the estimated completion of the study and publication of the results are expected in December 2027, pending recruitment.
Conclusions
The MAINSTREAM trial will determine the efficacy and safety of treatment with sacubitril/valsartan as a prevention of cardiotoxicity in patients with early breast cancer (ClinicalTrials.gov number: NCT05465031).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
- Department of Radiation and Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
- Department of Oncocardiology, Holy Cross Cancer Centre, Kielce, Poland.
- Holy Cross Cancer Centre, Kielce, Poland.
- Department of Oncology, Institute of Medical Sciences, University of Opole, Opole, Poland.
- Department of Clinical Oncology, Tadeusz Koszarowski Cancer Centre in Opole, Opole, Poland.
ORCID-Profile: Mateusz Tajstra, Maciej Dyrbuś, Tomasz Rutkowski, Krzysztof Składowski, Barbara Sosnowska-Pasiarska, Stanisław Góźdź, Barbara Radecka, Krzysztof Myrda, Alicja Nowowiejska-Wiewióra, Jolanta Nowak, Piotr Przybyłowski, Mariusz Gąsior, Michał Jarząb
Förderung
- Agencja Badań Medycznych
Zitieren
APA
Tajstra, M., Dyrbuś, M., Rutkowski, T., Składowski, K., Sosnowska-Pasiarska, B., Góźdź, S., Radecka, B., Staszewski, M., Majsnerowska, A., Myrda, K., Nowowiejska-Wiewióra, A., Skoczylas, I., Rymkiewicz, I., Niklewski, T., Nowak, J., Przybyłowski, P., Gąsior, M., & Jarząb, M. (2023). Sacubitril/Valsartan for Cardioprotection in Breast Cancer (MAINSTREAM): Design and Rationale of the Randomized Trial. ESC Heart Failure. https://doi.org/10.1002/ehf2.14466
Vancouver
Tajstra M, Dyrbuś M, Rutkowski T, Składowski K, Sosnowska-Pasiarska B, Góźdź S, et al. Sacubitril/Valsartan for Cardioprotection in Breast Cancer (MAINSTREAM): Design and Rationale of the Randomized Trial. ESC Heart Failure. 2023. doi:10.1002/ehf2.14466
BibTeX
@article{Tajstra2023,
author = {Tajstra, Mateusz and Dyrbuś, Maciej and Rutkowski, Tomasz and Składowski, Krzysztof and Sosnowska-Pasiarska, Barbara and Góźdź, Stanisław and Radecka, Barbara and Staszewski, Marek and Majsnerowska, Aleksandra and Myrda, Krzysztof and Nowowiejska-Wiewióra, Alicja and Skoczylas, Ilona and Rymkiewicz, Igor and Niklewski, Tomasz and Nowak, Jolanta and Przybyłowski, Piotr and Gąsior, Mariusz and Jarząb, Michał},
title = {Sacubitril/Valsartan for Cardioprotection in Breast Cancer (MAINSTREAM): Design and Rationale of the Randomized Trial},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14466}
}
EUVIMED